



CLIENT INFORMATION		ORDERING PHYSICIAN INFORMATION			
		Ordering Provider		Copy To Provider	
		NPI		NPI	
		Tel		Fax	
PATIENT INFORMATION					
Name (Last, First, MI)		DOB / /		Gender ☐ Male ☐ Female	
Address (City, State, Zip)		Tel		Client Patient ID	
BILLING INFORMATION					
☐ Facility ☐ Insurance ☐ Patient		Insurance Company (Attach copy of Insurance info)		Policy #	
				Group #	
Place of Service ☐ Hospital Inpatient ☐ On-Campus Hospital Outpatient ☐ Off-Campus Hospital Outpatient ☐ Physician Office					
CLINICAL AND SPECIMEN INFORMATION					
Diagnosis Codes		Specimen Source		Specimen ID	
Included ☐ CBC ☐ Pathology report					
Collection Date/Time / / _____ ☐ am ☐ pm		☐ Blood ☐ Bone Marrow ☐ Aspirate ☐ Core Biopsy ☐ Clot		Required for Breast Cancer Diagnostics: ☐ Zinc Fixed ☐ B-Plus Fixed ☐ 10% Neutral Buffered Formalin ☐ Time to Tissue Fixation: _____ ☐ Tissue Fixation Time: _____	
Clinical Diagnosis/Reason for Referral		☐ Fresh Tissue ☐ FNA ☐ Fluids Source ☐ Other Source _____		FFPE # of Blocks _____ # of Slides _____ ☐ Exhaust Block if necessary ☐ Call before exhausting Block	
PATHOLOGY & COMPREHENSIVE EVALUATION (STRATAFLEX)					
☐ BMPE Bone Marrow Pathology Evaluation					
☐ SPC Surgical Pathology Consultation					
☐ FLOW M (Global Flow Cytometry with morphology; peripheral blood only; client bill only)					
STRATAFLEX: MPLN Hematopathologists utilize MPLN's Strategic Reflex Testing approach to laboratory medicine and will recommend only the most appropriate reflex testing. All clinically relevant findings and analysis are provided in an integrated report.					
FLOW CYTOMETRY			MOLECULAR ONCOLOGY		
Select one: ☐ FLOW Global – Leukemia / Myeloma / Lymphoma ☐ FLOW TC Technical Only – Leukemia / Myeloma / Lymphoma ☐ If CLL clone identified, reflex to F CLL, M IgVH, and M TP53 ☐ FLOW PNH Paroxysmal Nocturnal Hemoglobinuria (PNH) – High Sensitivity			☐ M IgVH Somatic Hypermutation Analysis (CLL) ☐ M B-CELL Ig Heavy Chain Gene Rearrangement ☐ M TCR T-cell Receptor Gamma Gene Rearrangement ☐ M BCR ABL BCR/ABL1 qRT PCR ☐ M TP53 (Exons 2-11)		
For abbreviated panels Select one: ☐ Lymphoid markers only ☐ B-cell/plasma cell markers only ☐ Residual disease / other (please specify below) _____ ☐ FLOW BAL Bronchoalveolar Lavage (CD4/CD8 ratio)			☐ M JAK2 V617F Mutation by PCR with reflex to ☐ M NGS HEME ☐ M MYD88 (p. L265P) Mutation ☐ M KIT P* (D816V Mutation) by PCR for Mastocytosis ☐ M FLT3 ☐ M NGS HEME (ASXL1, CALR, CBL, CEBPA, CSF3R, DNMT3A, EZH2, (TKD), IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, UZAF1, WT1, ZRSR2)		
CYTOGENETICS					
☐ CYTO BM Chromosome Analysis on Bone Marrow ☐ CYTO LPB Chromosome Analysis on Leukemic Peripheral Blood (Oncology) ☐ CYTO LN Chromosome Analysis for Lymphoma (Lymph Node or other tissue)					
FLUORESCENT IN SITU HYBRIDIZATION (FISH)			BREAST PROGNOSTIC MARKERS		
☐ F AML::ETO t(8;21) ☐ F AML FRONTLINE Acute Myeloid Leukemia Panel 5pq, 7/7q, t(8;21), CBFB, KMT2A ☐ F AML SECONDARY MECOM, NUP98, t(6;9), t(9;22), TP53 ☐ F BCL3 19q13.3 Rearrangement ☐ F BCL6 3q27 Rearrangement ☐ F BCR::ABL1 t(9;22) Reflex to: ☐ M JAK2 V617F Mutation ☐ F BURKITT “Double Hit” Large B-cell Lymphoma Panel [CMYC, t(8;14), BCL2, BCL6] ☐ F CBFB t(16;16), inv(16) ☐ F CLL Chronic Lymphocytic Leukemia Panel ☐ F CMYC 8q24 Rearrangement ☐ F EOS Eosinophilia Panel (4q12, PDGFRB, FGFR1) ☐ F DEK::NUP214 t(6;9) ☐ F FGFR1 8p11.2 Rearrangement ☐ F IGH 14q32 Rearrangement ☐ F IGH::FGRF3 t(4;14)			☐ I ER Estrogen Receptor ☐ I HER2 HER2/Neu (IVD) Reflex to: ☐ FP HER2/Neu ☐ I Ki67 Cell Proliferation Marker ☐ IP53 Tumor Suppressor Gene Protein ☐ IPR Progesterone Receptor		
			SOLID TUMOR MOLECULAR		
			☐ M BRAF (Exon 15) ☐ M EGFR (Exons 12, 18 - 21) ☐ M KRAS (Exons 2, 3, 4) ☐ M COLON NGS Colorectal- BRAF, KRAS, NRAS		
			SOLID TUMOR FISH / IHC		
☐ F IGH::MYC t(8;14) ☐ F IGH::CCND1 t(11;14) ☐ F IGH::MAF t(14;16) ☐ F IGH::BCL2 t(14;18) ☐ F IGH::MALT1 t(14;18) ☐ F IRF4 6p25 Rearrangement ☐ F MALT1 18q21 Rearrangement ☐ F MECOM 3q26.2 Rearrangement ☐ F MDS Myelodysplastic Syndrome Panel ☐ F MLL KMT2A 11q23 Rearrangement ☐ F MM Multiple Myeloma Panel ☐ F MPD Myeloproliferative Neoplasm Panel (9;22 included) ☐ F NUP98 11p15 Rearrangement ☐ F 4q12 FIP1L1/CHIC2/PDGFRΑ Rearrangement ☐ F PDGFRB 5q32 Rearrangement ☐ F PRDM16 1p36.32 Rearrangement ☐ F PML::RARA t(15;17) ☐ F URO Bladder Cancer Panel [+3, +7, +17, 9p21-] ☐ F FEV6::RUNX11 t(12;21)			☐ FP ALK 2p23 Rearrangement ☐ FP HER2/Neu Breast ☐ FP HER2 GA HER2/neu Gastric ☐ FP BURKITT “Double Hit” Large B-cell Lymphoma Panel [CMYC, t(8;14), BCL2, BCL6] ☐ FP BCL6 3q27 Rearrangement ☐ FP CMYC 8q24 Rearrangement ☐ FP IGH 14q32 Rearrangement ☐ FP IGH::MYC t(8;14) ☐ FP IGH::CCND1 t(11;14) ☐ FP IGH::BCL2 t(14;18) ☐ FP IRF4 6p25 Rearrangement ☐ FP MALT1 18q21 Rearrangement ☐ I MSI Microsatellite instability profile (Mismatch repair) ☐ I PD-L1 Clone SP263, tumor prognostic marker ☐ FP ROS1 6p22 Rearrangement		
COMMENTS					
Please Note: Many payers, including Medicare and Medicaid, have medical necessity requirements. You should only order tests which are medically necessary for the diagnosis and treatment of the patient. Thank you.					
* Performed at affiliate laboratory					
All other IHC stains are on a separate requisition. For a complete list including FISH Probes, visit www.MPLNet.com AUG 2025					